Xilio Therapeutics Past Earnings Performance
Past criteria checks 0/6
Xilio Therapeutics's earnings have been declining at an average annual rate of -17.4%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
-17.4%
Earnings growth rate
77.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -207.5% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How Xilio Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -76 | 27 | 52 |
| 30 Sep 23 | 0 | -81 | 29 | 55 |
| 30 Jun 23 | 0 | -84 | 30 | 57 |
| 31 Mar 23 | 0 | -90 | 31 | 60 |
| 31 Dec 22 | 0 | -88 | 30 | 59 |
| 30 Sep 22 | 0 | -85 | 30 | 56 |
| 30 Jun 22 | 0 | -82 | 28 | 53 |
| 31 Mar 22 | 0 | -80 | 25 | 54 |
| 31 Dec 21 | 0 | -76 | 24 | 51 |
| 30 Sep 21 | 0 | -77 | 19 | 58 |
| 30 Jun 21 | 0 | -75 | 16 | 58 |
| 31 Mar 21 | 0 | -64 | 13 | 50 |
| 31 Dec 20 | 0 | -55 | 11 | 44 |
Quality Earnings: XLO is currently unprofitable.
Growing Profit Margin: XLO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: XLO is unprofitable, and losses have increased over the past 5 years at a rate of 17.4% per year.
Accelerating Growth: Unable to compare XLO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XLO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: XLO has a negative Return on Equity (-207.47%), as it is currently unprofitable.